WESTERN UNIVERSITY OF HEALTH SCIENCES;TESORX PHARMA, LLC;TESORX PHARMA, LLC;泰索克斯制藥有限責任公司
发明人:
Guru V. BETAGERI,Natarajan VENKATESAN,Michael G. OEFELEIN,N‧溫卡德森,Michael G. OEFELEIN,M‧G‧厄夫來因
申请号：
HK18114340
公开号：
HK1255212A1
申请日:
2018.11.09
申请国别(地区):
HK
年份:
2019
代理人:
摘要：
Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.
